PROTAGONIST THERAPEUTICS INC's ticker is PTGX and the CUSIP is 74366E102. A total of 145 filers reported holding PROTAGONIST THERAPEUTICS INC in Q3 2023. The put-call ratio across all filers is 0.11 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $65,754,862 | -33.0% | 3,942,138 | +11.0% | 0.00% | -20.0% |
Q2 2023 | $98,105,853 | +76.7% | 3,551,986 | +47.2% | 0.01% | +66.7% |
Q1 2023 | $55,514,803 | -32.9% | 2,413,701 | -68.2% | 0.00% | +50.0% |
Q4 2022 | $82,761,646 | +109.9% | 7,585,852 | +62.2% | 0.00% | 0.0% |
Q3 2022 | $39,424,000 | -26.4% | 4,676,682 | -31.0% | 0.00% | -33.3% |
Q2 2022 | $53,600,000 | -30.5% | 6,776,269 | +108.1% | 0.00% | -25.0% |
Q1 2022 | $77,121,000 | -12.3% | 3,256,808 | +26.6% | 0.00% | 0.0% |
Q4 2021 | $87,948,000 | +146.4% | 2,571,570 | +27.7% | 0.00% | +100.0% |
Q3 2021 | $35,688,000 | -45.3% | 2,013,979 | +38.5% | 0.00% | -33.3% |
Q2 2021 | $65,283,000 | +47.2% | 1,454,620 | -15.1% | 0.00% | 0.0% |
Q1 2021 | $44,358,000 | +48.2% | 1,712,683 | +15.4% | 0.00% | +50.0% |
Q4 2020 | $29,924,000 | +32.6% | 1,484,316 | +28.6% | 0.00% | 0.0% |
Q3 2020 | $22,572,000 | +233.8% | 1,154,553 | +201.5% | 0.00% | – |
Q2 2020 | $6,762,000 | +201.3% | 382,894 | +20.5% | 0.00% | – |
Q1 2020 | $2,244,000 | -5.9% | 317,792 | -6.0% | 0.00% | – |
Q4 2019 | $2,384,000 | -37.0% | 338,170 | +7.3% | 0.00% | – |
Q3 2019 | $3,784,000 | +19.0% | 315,043 | +19.9% | 0.00% | – |
Q2 2019 | $3,181,000 | +1697.2% | 262,710 | +1769.6% | 0.00% | – |
Q1 2019 | $177,000 | +84.4% | 14,052 | -1.7% | 0.00% | – |
Q4 2018 | $96,000 | -36.4% | 14,298 | -2.3% | 0.00% | – |
Q3 2018 | $151,000 | +57.3% | 14,640 | +1.8% | 0.00% | – |
Q2 2018 | $96,000 | -92.7% | 14,378 | -90.6% | 0.00% | – |
Q1 2018 | $1,313,000 | -53.9% | 152,982 | +11.8% | 0.00% | – |
Q4 2017 | $2,847,000 | +37.5% | 136,844 | +16.8% | 0.00% | – |
Q3 2017 | $2,071,000 | +63.1% | 117,183 | +4.2% | 0.00% | – |
Q2 2017 | $1,270,000 | +6.5% | 112,474 | +20.9% | 0.00% | – |
Q1 2017 | $1,192,000 | -41.2% | 93,063 | +1.0% | 0.00% | – |
Q4 2016 | $2,028,000 | +57.0% | 92,163 | +50.8% | 0.00% | – |
Q3 2016 | $1,292,000 | – | 61,121 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
JOHNSON & JOHNSON | 2,449,183 | $20,647,000 | 6.08% |
Bain Capital Life Sciences Investors, LLC | 2,260,572 | $19,057,000 | 2.28% |
Kynam Capital Management, LP | 519,212 | $4,377,000 | 0.92% |
RTW INVESTMENTS, LP | 4,176,837 | $35,211,000 | 0.81% |
Tri Locum Partners LP | 199,500 | $1,682,000 | 0.46% |
Birchview Capital, LP | 38,000 | $320,000 | 0.22% |
Gratus Capital, LLC | 206,113 | $1,738,000 | 0.18% |
FARALLON CAPITAL MANAGEMENT LLC | 3,651,887 | $30,785,000 | 0.17% |
PDT Partners, LLC | 126,038 | $1,063,000 | 0.16% |
FOX RUN MANAGEMENT, L.L.C. | 40,683 | $343,000 | 0.13% |